# Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

> **NCT06734130** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Castration Sensitive Prostate Cancer

## Interventions

- **DRUG:** Luteinizing Hormone-Releasing Hormone (LHRH) analog
- **DRUG:** Androgen Receptor Signal Inhibitor (ARSI)
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06734130
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06734130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06734130, "Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06734130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*